A neuro-oncologist is a physician who specializes in diagnosing and treating cancers of the brain, spinal cord, and surrounding nervous system. The field sits at the intersection of neurology and oncology, and practitioners spend their days navigating one of medicine’s toughest challenges: fighting tumors in the most complex and protected organ in the body. The specialty emerged in the late 1960s and 1970s, when chemotherapy drugs first began to be tested against brain tumors, and it has grown into a discipline that blends molecular diagnostics, targeted therapies, symptom management, and palliative care into a single clinical practice.
How Neuro-Oncology Became Its Own Field
The roots of neuro-oncology trace back to the introduction of carmustine chemotherapy in the late 1960s. Before that, brain tumors were largely the domain of neurosurgeons and radiation therapists. Once anticancer drugs entered the picture, a new kind of physician emerged: someone trained to investigate and administer these agents against gliomas, medulloblastomas, and metastatic tumors in the central nervous system. In parallel, a second branch of the specialty developed more closely allied with neurology, focusing on the neurological complications of cancer and pain management.1JAMA Neurology. Neuro-oncology: An Overview Today, neuro-oncologists come from various medical backgrounds. Some train first in neurology, others in medical oncology, and a smaller number arrive through neurosurgery or radiation oncology before completing fellowship training in neuro-oncology.
A survey of the Italian Association for Neuro-Oncology found that about a third of practitioners considered residency training the single most important step in their neuro-oncology education, with younger physicians rating their residency programs more favorably than older colleagues. More than half said that reading the scientific literature was their primary tool for staying current, while roughly six in ten preferred dedicated courses and conferences as the ideal learning format.2SpringerOpen / Journal of Neuro-Oncology. Education paths in neuro-oncology: combining technical skills with multidisciplinary care The field moves fast enough that keeping up with new molecular classifications, trial results, and device approvals is itself a significant part of the job.
What Conditions Neuro-Oncologists Treat
The scope of a neuro-oncologist’s practice is broader than most people expect. The conditions they manage include:
- Primary brain tumors: cancers that originate in the brain itself, such as glioblastoma, astrocytoma, oligodendroglioma, meningioma, and ependymoma.
- Brain metastases: cancers that started elsewhere in the body and spread to the brain. These are actually more common than primary brain tumors, with lung, breast, and melanoma being frequent culprits.
- Spinal cord tumors: growths within or adjacent to the spinal cord that can compress nerves and cause pain, weakness, or paralysis.
- Leptomeningeal disease: cancer cells that spread into the fluid and membranes surrounding the brain and spinal cord, requiring specialized treatment approaches including intrathecal therapy, systemic drugs, and focal radiation.3PubMed Central. How we treat patients with leptomeningeal metastases
- Neurological complications of cancer treatment: side effects from chemotherapy, radiation, or immunotherapy that affect brain and nerve function.
Brain metastases alone represent a substantial workload. A review at one tertiary neuro-oncology center found that patients with brain metastases made up about 22% of all cases discussed at their multidisciplinary team meetings over a two-year period.4PubMed. Two-year experience of multi-disciplinary team (MDT) outcomes for brain metastases in a tertiary neuro-oncology centre
The Multidisciplinary Team Approach
Neuro-oncologists rarely work alone. Treating a brain tumor almost always involves a coordinated team that includes neurosurgeons, radiation oncologists, neuroradiologists, neuropathologists, neuropsychologists, rehabilitation specialists, and palliative care providers. Multidisciplinary clinics have become the standard of care for cancer treatment across the United States, and specialty clinics focused on particular tumor types have been shown to improve both patient outcomes and satisfaction.5PubMed Central. Multidisciplinary pediatric brain tumor clinics: the key to successful treatment?
In practice, this means a neuro-oncologist often serves as the quarterback of the care team. After a neurosurgeon removes or biopsies the tumor, the neuro-oncologist reviews the pathology and molecular results, designs the treatment plan, coordinates radiation therapy schedules, prescribes and monitors chemotherapy, manages side effects, and tracks whether the tumor is responding or progressing on follow-up imaging. At regular tumor board meetings, the team reviews each patient’s scans and clinical status together. At the tertiary center mentioned above, a concrete treatment decision was reached for about 78% of patients discussed at these meetings, with roughly a third of those decisions involving neurosurgical input.4PubMed. Two-year experience of multi-disciplinary team (MDT) outcomes for brain metastases in a tertiary neuro-oncology centre
Molecular Diagnostics and Tumor Classification
One of the biggest shifts in neuro-oncology over the past two decades has been the move from classifying brain tumors purely by how they look under a microscope to classifying them by their molecular fingerprint. This matters enormously because two tumors that appear identical under the microscope can behave completely differently depending on their genetic makeup, and the right treatment depends on getting the molecular picture right. Molecular markers now play a central role in classification, prognosis, survival estimates, and therapy decisions for different glioma subtypes.6PubMed Central. IDH mutation and MGMT methylation status in glioblastoma and other gliomas patients
The most widely validated markers in neuro-oncology today include IDH1/2 mutations, which distinguish less aggressive gliomas from glioblastomas; co-deletion of chromosomal arms 1p and 19q, which differentiates oligodendrogliomas from astrocytomas; MGMT promoter methylation, which predicts how well a glioblastoma will respond to the standard chemotherapy drug; and select pathway-associated mutations that can open the door to targeted therapies.7PubMed Central. Actionable molecular biomarkers in primary brain tumors A neuro-oncologist interprets these results and explains to patients what they mean for prognosis and which treatment options make sense. This is a conversation that requires real fluency in both the molecular science and the human side of delivering complex, often frightening, information.
The Blood-Brain Barrier Problem
One reason brain tumors are so difficult to treat is the blood-brain barrier, a tightly sealed layer of cells lining the blood vessels in the brain that prevents most drugs from reaching the tumor. Many chemotherapy agents that work well against cancers in other organs simply cannot cross this barrier in effective concentrations. Neuro-oncologists must factor this into every treatment decision.
Researchers have developed a range of strategies to get around this obstacle. These include giving chemotherapy at high intravenous doses to force more drug across the barrier, delivering drugs directly into the arteries feeding the tumor, implanting drug-releasing wafers or catheters at the surgical site, physically disrupting the barrier, and chemically modifying drugs to make them more permeable.8PubMed Central. Drug delivery to brain tumors More recent work has drawn a useful distinction between strategies that aim to disrupt the barrier and those that aim to circumvent it entirely, such as convection-enhanced delivery or nanoparticle-based systems.9PubMed Central. Therapeutic strategies to improve drug delivery across the blood-brain barrier Understanding these options and choosing the right one for a given patient and tumor is a core part of the neuro-oncologist’s expertise.
Treatments a Neuro-Oncologist Prescribes and Monitors
The standard first-line treatment for the most common and aggressive primary brain tumor, glioblastoma, involves surgery followed by radiation combined with temozolomide, an oral chemotherapy drug. Temozolomide works by attaching a chemical group to DNA in tumor cells, disrupting their ability to replicate. It is used frequently alongside radiation as part of the initial treatment plan for high-grade gliomas.10PubMed Central. Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications The neuro-oncologist prescribes the drug, sets the dosing schedule, monitors blood counts (since temozolomide can suppress the bone marrow), and adjusts the regimen as needed.
A newer addition to the treatment landscape is tumor-treating fields, a device-based therapy that uses low-intensity alternating electric fields delivered through arrays worn on the scalp. These fields interfere with cell division by disrupting the structures that pull chromosomes apart during mitosis, effectively slowing or stopping tumor growth while leaving non-dividing cells largely unaffected.11Neuro-Oncology. Tumor treating fields: a novel treatment modality and its use in brain tumors Randomized trials showed that adding tumor-treating fields to standard therapy extends survival for patients with newly diagnosed glioblastoma, and the approach has received FDA approval.12British Journal of Cancer. Tumour treating fields therapy for glioblastoma: current advances and future directions Neuro-oncologists discuss this option with eligible patients, help them understand the commitment involved (the device needs to be worn for at least 18 hours a day), and coordinate the fitting and monitoring.
Managing Symptoms and Side Effects
A large part of what neuro-oncologists do has nothing to do with attacking the tumor directly. Brain tumors cause a constellation of symptoms that need active management, and the treatments themselves carry their own neurological risks.
Swelling around the tumor is one of the most immediate concerns. Corticosteroids are the workhorse for controlling this edema, but neuro-oncologists use them carefully: in the minimum dose needed to control symptoms, tapered as quickly as possible, because long-term steroid use causes significant side effects including weight gain, bone thinning, muscle weakness, and mood changes. Patients who need extended steroid treatment require monitoring for adrenal insufficiency.13PubMed. Medical management of patients with brain tumors
Seizures are another common issue. Current guidelines recommend antiseizure medications only for patients who have actually had a seizure, not as a preventive measure for all brain tumor patients. The choice of drug matters, because some older antiseizure medications interfere with chemotherapy metabolism. Levetiracetam is often preferred because it has fewer drug interactions and is available in both oral and intravenous forms.13PubMed. Medical management of patients with brain tumors
Immunotherapy, increasingly used in brain tumor care, brings its own set of neurological complications. Close monitoring for neurological symptoms is essential for catching immunotherapy-related side effects early, since delayed recognition can lead to lasting deficits.14PubMed. Neurological complications of cancer immunotherapy These complications can affect the brain, spinal cord, peripheral nerves, or neuromuscular junction, and neuro-oncologists are trained to distinguish them from tumor progression or other causes.15PubMed Central. Neurologic Complications of Cancer Immunotherapy
Telling Real Progression from False Alarms
One of the trickiest parts of following brain tumor patients is interpreting what happens on MRI scans after treatment. After radiation and chemotherapy, up to a third of glioblastoma patients develop what looks like tumor growth on a standard MRI but is actually pseudoprogression: a treatment-related inflammatory reaction that mimics tumor recurrence. Standard structural MRI alone is not reliable enough to tell the two apart.16PubMed Central. Pseudoprogression of brain tumors
Getting this distinction right has real consequences. If a neuro-oncologist mistakes pseudoprogression for true tumor growth, the patient might be switched to a second-line therapy prematurely, losing the benefit of a treatment that was actually working. Advanced imaging techniques, including perfusion MRI and MR spectroscopy, help improve the diagnostic accuracy, with some combinations reaching above 90%.16PubMed Central. Pseudoprogression of brain tumors Machine learning approaches are also being developed; one model using multiple MRI parameters achieved 85% accuracy in distinguishing true progression from pseudoprogression.17Neuro-Oncology Advances. Distinction of pseudoprogression from true progression in glioblastomas using machine learning based on multiparametric magnetic resonance imaging and O6-methylguanine-methyltransferase promoter methylation status
To standardize how tumors are measured and how treatment response is reported, the field developed the Response Assessment in Neuro-Oncology (RANO) criteria. These guidelines give neuro-oncologists and neuroradiologists a shared framework for deciding whether a tumor has responded, remained stable, or progressed. The criteria have been updated over time to accommodate new treatment approaches including immunotherapy.18PubMed Central. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults
Differences Between Pediatric and Adult Neuro-Oncology
Brain tumors in children and adults are strikingly different diseases, and the neuro-oncology subspecialty reflects this. Compared with adult brain tumors, pediatric tumors tend to be more responsive to radiation and chemotherapy, but they also more often require treatment of the entire brain and spinal cord because of their tendency to spread through the cerebrospinal fluid.19PubMed Central. Brain tumors across the age spectrum: biology, therapy, and late effects The tumor types themselves differ: medulloblastoma is far more common in children, while high-grade gliomas in the cerebral hemispheres dominate in adults.
Some tumor types do overlap between age groups, but they behave differently. Medulloblastoma, pilocytic astrocytoma, and craniopharyngioma all occur in both adults and children, yet their classification, treatment approach, and outcomes differ substantially between the two populations.20PubMed Central. Typical Pediatric Brain Tumors Occurring in Adults-Differences in Management and Outcome Even when the same molecular subtype appears across ages, treatment patterns diverge. A study comparing IDH-mutant gliomas in pediatric, young adult, and older adult patients found that children were more likely to receive complete surgical resection (about half, compared with roughly a quarter of older adults) and far less likely to receive upfront radiation or chemotherapy.21Neuro-Oncology. A comparative analysis of IDH-mutant glioma in pediatric, young adult, and older adult patients Pediatric neuro-oncologists must also contend with the long-term effects of treatment on a developing brain, including cognitive, hormonal, and growth-related consequences that may not emerge for years.
Palliative Care and Quality of Life
Because many brain tumors carry a serious prognosis, palliative care is woven into neuro-oncology from the start, not reserved for the end. Patients with brain tumors face unique symptoms from diagnosis onward, including cognitive changes, personality shifts, fatigue, communication difficulties, and loss of independence, all requiring interventions that draw on multiple disciplines.22PubMed Central. Palliative care and quality of life in neuro-oncology Neuro-oncologists are well positioned to provide this kind of care because they already manage the neurological symptoms and understand how treatment decisions affect daily functioning.23PubMed. Palliative Care in Neuro-oncology
In practice, this means having direct conversations about goals of care early and often. It means helping patients and families weigh the potential survival benefit of an aggressive treatment against its impact on cognitive function and quality of life. It means managing pain, nausea, and psychological distress alongside tumor-directed therapy. For many patients, maintaining independence and mental clarity matters as much as, or more than, extending life by a few weeks.
Cognitive Rehabilitation for Brain Tumor Survivors
Cognitive problems are one of the most common and distressing effects of brain tumors and their treatment. Memory difficulties, trouble concentrating, slowed processing, and impaired executive function (planning, organizing, multitasking) affect a large proportion of patients. Neuro-oncologists increasingly coordinate cognitive rehabilitation as part of comprehensive care.
A pilot randomized trial tested a structured behavioral intervention called Goal Management Training, which combines mindfulness and strategy training, in brain tumor survivors with executive dysfunction. Participants who received the training showed improved executive function compared with control groups, and the gains held up at a four-month follow-up.24PubMed. Cognitive rehabilitation for executive dysfunction in brain tumor patients: a pilot randomized controlled trial Technology is also entering the picture. A telerehabilitation app called ReMind, designed specifically for brain tumor patients and incorporating psychoeducation, strategy training, and retraining exercises, was found to be feasible for use in a clinical setting, opening the door to rehabilitation that patients can do from home.25PubMed Central. Feasibility of the evidence-based cognitive telerehabilitation program Remind for patients with primary brain tumors The evidence base here is still relatively early-stage, but it represents a shift toward treating the whole patient rather than focusing exclusively on the tumor.
CAR-T Cell Therapy and the Next Frontier
Immunotherapy has transformed the treatment of many cancers, but brain tumors have been stubbornly resistant to most immune-based approaches. One of the most closely watched developments is CAR-T cell therapy, in which a patient’s own immune cells are engineered in a laboratory to recognize and attack specific proteins on the tumor surface, then infused back into the patient.
Early-phase trials are producing cautiously encouraging results. In one phase I trial, CAR-T cells targeting a protein called IL13Rα2 were given to 65 patients and achieved a disease-control rate of about 50%, with roughly one in four patients surviving at least a year.26PubMed Central. CAR-T cell therapies are coming after glioblastoma: An overview of early phase clinical trials and future perspectives Researchers are targeting several different proteins on glioblastoma cells; across early trials reviewed systematically, the EGFR family and IL13Rα2 have been the most common targets, with GD2, EphA2, and PD-L1 also being explored.27Neuro-Oncology Advances. Chimeric antigen receptor (CAR)-T-cell therapy for glioblastoma: what can we learn from the early clinical trials? A systematic review
Pediatric brain tumors are also getting attention. A first-in-human phase I trial tested CAR-T cells targeting B7-H3, a protein found on many pediatric central nervous system tumors, delivered directly into the cerebrospinal fluid of children with diffuse intrinsic pontine glioma and other recurrent brain tumors. The trial found the approach tolerable, including in patients who received repeated doses over multiple years, and the results were promising enough to warrant a larger phase 2 study.28Nature Medicine. Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial For neuro-oncologists, staying on top of these trials, identifying patients who might be eligible, and managing the novel side effects these therapies can produce (including potentially serious brain inflammation) is becoming an increasingly important part of the job.
When to See a Neuro-Oncologist
Most people are referred to a neuro-oncologist after imaging reveals a brain or spinal tumor, usually following symptoms like new-onset seizures, persistent headaches, vision changes, weakness on one side of the body, or personality and cognitive changes. The referral typically comes from a neurologist, neurosurgeon, or general oncologist. In some cases, a primary care physician makes the referral directly after a scan shows something concerning.
If you or a family member has been diagnosed with a brain tumor, asking whether a neuro-oncologist is available, particularly at an academic medical center with a multidisciplinary brain tumor program, is reasonable and often worthwhile. These specialists see a higher volume of brain tumors than most general oncologists, have access to clinical trials, and are trained to navigate the specific complexities of treating cancer in the nervous system. For rare or hard-to-treat tumors, a second opinion from a neuro-oncologist at a major center can sometimes change the diagnosis, the molecular classification, or the treatment plan in ways that matter for outcomes.